AMM is the preeminent source of mRNA studies and data. In addition to publishing original research on the state of mRNA worldwide, we serve as an aggregator of the latest studies from the field. Explore below to learn more about recent advancements in mRNA technology.
Featured Study
Advancing mRNA: Executive Insights and Future Directions explores industry perspectives on the expanding role of mRNA beyond vaccines, highlighting opportunities in oncology, rare diseases, and gene therapy. The study examines investment trends, regulatory challenges, and the future of mRNA therapeutics in medicine.
mRNA-based therapeutics: powerful and versatile tools to combat diseases
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or therapeutic agent.
COVID-19 mRNA vaccines: Platforms and current developments
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in a preclinical study nearly 30 years ago, numerous advances have been made in the field of mRNA therapeutic technologies.
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic.
Current Status and Future Perspectives on MRNA Drug Manufacturing
The COVID-19 pandemic has catapulted mRNA (mRNA)vaccines from a relatively niche technology into the mainstream, with several hundred million doses of mRNA vaccines being administered.
A new study published in Nature by BioNTech, in collaboration with Genentech, demonstrates how an individualized mRNA-based neoantigen vaccine, autogene cevumeran, combined with the PD-L1 inhibitor atezolizumab, induces long-lasting CD8+ T cell responses in pancreatic cancer patients.
